Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII - an open label, exploratory, cross-over, phase I/II study

Haemophilia

Volumn 16, Issue 6, 2010, Pages 910-918

  Spira, J ^a   Plyushch, O ^b   Zozulya, N ^b   Yatuv, R ^a   Dayan, I ^a   Bleicher, A ^a   Robinson, M ^a   Baru, Moshe ^a  

^a Omri Laboratories Ltd   (Israel)

^b NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

Author keywords

Factor VIIa; Long acting; PEGylated liposomes

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHATIDYLETHANOLAMINE N [METHOXY(POLYETHYLENEGLYCOL) 2000]; 2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; BLOOD CLOTTING FACTOR 8 INHIBITOR; D DIMER; FIBRINOGEN; LIPOSOME; MACROGOL 2000; PHOSPHATIDYLETHANOLAMINE; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CHEMISTRY; BLOOD CLOTTING; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; HEART RATE; HEMATOLOGICAL PARAMETERS; HEMOPHILIA A; HEMOSTASIS; HUMAN; MEAN RESIDENCE TIME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOELASTOGRAPHY; THROMBOSIS;

BLOOD COAGULATION FACTOR INHIBITORS; CROSS-OVER STUDIES; FACTOR VIIA; FACTOR VIII; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEMOPHILIA A; HUMANS; LIPOSOMES; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; POLYETHYLENE GLYCOLS; PROTEIN PRECURSORS; PROTHROMBIN; THROMBELASTOGRAPHY; THROMBIN;

EID: 78049295599     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02273.x     Document Type: Article

References (36)

1. Hedner U, Glazer S, Pingel K et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
2. Lusher JM, Roberts HR, Davignon G et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4: 790-8.
3. Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005; 16: 259-66.
4. Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
5. Ingerslev J, Thykjaer H, Kudsk Jensen O, Fredberg U. Home treatment with recombinant activated factor VII: results from one centre. Blood Coagul Fibrinolysis 1998; 9(Suppl. 1): S107-10.
6. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
7. Hedner U. Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Dis Mon 2003; 49: 39-48.
8. Abshire TC. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing. Semin Hematol 2004; 41: 3-7.
9. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1: 450-5.
10. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
11. Ng HJ, Lee LH. Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients. Vasc Health Risk Manag 2006; 2: 433-40.
12. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999; 5(Suppl. 3): 11-7.
13. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8.
14. Yatuv R, Carmel-Goren L, Dayan I, Robinson M, Baru M. Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells. J Control Release 2009; 135: 44-50.
15. Yatuv R, Dayan I, Carmel-Goren L et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008; 14: 476-83.
16. Yatuv R, Robinson M, Dayan I, Baru M. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. Expert Opin Drug Deliv 2010; 7: 187-201.
17. Baru M, Carmel-Goren L, Barenholz Y et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005; 93: 1061-8.
18. Dayan I, Robinson M, Baru M. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes. Haemophilia 2009; 15: 1006-13.
19. Powell JS, Nugent DJ, Harrison JA et al. Safety and pharmacokinetics of a recombinant factor VIII with PEGylated liposomes in severe hemophilia A. J Thromb Haemost 2008; 6: 277-83.
20. Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006; 108: 3668-73.
21. Spira J, Plyushch OP, Andreeva TA, Khametova RN. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 2008; 100: 429-34.
22. Martinowitz U, Lalezari S, Luboshitz J, Lubetsky A, Spira J. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A. Haemophilia 2008; 14: 1122-4.
23. Hemker HC, Giesen P, Al Dieri R et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
24. Butenas S, Brummel KE, Bouchard BA, Mann KG. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1: 1158-60.
25. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005; 216: 106-21.
26. Hayashi T, Tanaka I, Shima M et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10: 397-400.
27. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
28. Baudo F, Redaelli R, Caimi TM, Mostarda G, Somaini G, De Cataldo F. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res 2000; 99: 21-4.
29. Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia 2007; 13: 527-32.
30. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006; 32(Suppl. 1): 77-85.
31. Pan J, Liu T, Kim JY et al. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood 2009; 114: 2802-11.
32. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 645-55.
33. Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 27: 683-9.
34. Liu T, Zhang X, Pan J et al. Enhanced and prolonged efficacy of a novel recombinant FVIIa variant (BAY86-6150) for acute and prophylactic treatments in hemophilia A (HemA) mice. J Thromb Haemost 2009; 7: OC-WE 057.
35. Stennicke HR, Ostergaard H, Bayer RJ et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008; 100: 920-8.
36. Moss J, Rosholm A, Laurén A. Safety and pharmacokinetics of a long-acting glycopegylated rFVIIa derivative: a first human dose trial in healthy subjects. J Thromb Haemost 2009; 7: OC-WE-055.